These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 1958230)
1. (2,6-Dimethylphenylsulphonyl)nitromethane: a new structural type of aldose reductase inhibitor which follows biphasic kinetics and uses an allosteric binding site. Ward WH; Cook PN; Mirrlees DJ; Brittain DR; Preston J; Carey F; Tuffin DP; Howe R Biochem Pharmacol; 1991 Nov; 42(11):2115-23. PubMed ID: 1958230 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of aldose reductase by (2,6-dimethylphenylsulphonyl)nitromethane: possible implications for the nature of an inhibitor binding site and a cause of biphasic kinetics. Ward WH; Cook PN; Mirrlees DJ; Brittain DR; Preston J; Carey F; Tuffin DP; Howe R Adv Exp Med Biol; 1993; 328():301-11. PubMed ID: 8493907 [TBL] [Abstract][Full Text] [Related]
3. Ponalrestat: a potent and specific inhibitor of aldose reductase. Ward WH; Sennitt CM; Ross H; Dingle A; Timms D; Mirrlees DJ; Tuffin DP Biochem Pharmacol; 1990 Jan; 39(2):337-46. PubMed ID: 2105733 [TBL] [Abstract][Full Text] [Related]
4. Kinetic characteristics of ZENECA ZD5522, a potent inhibitor of human and bovine lens aldose reductase. Cook PN; Ward WH; Petrash JM; Mirrlees DJ; Sennitt CM; Carey F; Preston J; Brittain DR; Tuffin DP; Howe R Biochem Pharmacol; 1995 Apr; 49(8):1043-9. PubMed ID: 7748183 [TBL] [Abstract][Full Text] [Related]
5. Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. Carbone V; Zhao HT; Chung R; Endo S; Hara A; El-Kabbani O Bioorg Med Chem; 2009 Feb; 17(3):1244-50. PubMed ID: 19121944 [TBL] [Abstract][Full Text] [Related]
6. Inhibition kinetics of human kidney aldose and aldehyde reductases by aldose reductase inhibitors. Bhatnagar A; Liu SQ; Das B; Ansari NH; Srivastava SK Biochem Pharmacol; 1990 Mar; 39(6):1115-24. PubMed ID: 2157439 [TBL] [Abstract][Full Text] [Related]
7. Mechanism of human aldehyde reductase: characterization of the active site pocket. Barski OA; Gabbay KH; Grimshaw CE; Bohren KM Biochemistry; 1995 Sep; 34(35):11264-75. PubMed ID: 7669785 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of hexonate dehydrogenase and aldose reductase from bovine retina by sorbinil, statil, M79175 and valproate. Poulsom R Biochem Pharmacol; 1986 Sep; 35(17):2955-9. PubMed ID: 3091036 [TBL] [Abstract][Full Text] [Related]
12. Development of coumarin-thiosemicarbazone hybrids as aldose reductase inhibitors: Biological assays, molecular docking, simulation studies and ADME evaluation. Imran A; Tariq Shehzad M; Al Adhami T; Miraz Rahman K; Hussain D; Alharthy RD; Shafiq Z; Iqbal J Bioorg Chem; 2021 Oct; 115():105164. PubMed ID: 34314916 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of aldehyde reductase by aldose reductase inhibitors. Sato S; Kador PF Biochem Pharmacol; 1990 Sep; 40(5):1033-42. PubMed ID: 2117925 [TBL] [Abstract][Full Text] [Related]
14. Inhibitory activity and mechanism of inhibition of the N-[[(4-benzoylamino)phenyl]sulfonyl]amino acid aldose reductase inhibitors. DeRuiter J; Mayfield CA Biochem Pharmacol; 1990 Nov; 40(10):2219-26. PubMed ID: 2123105 [TBL] [Abstract][Full Text] [Related]
15. Enhancing activity and selectivity in a series of pyrrol-1-yl-1-hydroxypyrazole-based aldose reductase inhibitors: The case of trifluoroacetylation. Papastavrou N; Chatzopoulou M; Ballekova J; Cappiello M; Moschini R; Balestri F; Patsilinakos A; Ragno R; Stefek M; Nicolaou I Eur J Med Chem; 2017 Apr; 130():328-335. PubMed ID: 28259841 [TBL] [Abstract][Full Text] [Related]
16. 1-Hydroxypyrazole as a bioisostere of the acetic acid moiety in a series of aldose reductase inhibitors. Papastavrou N; Chatzopoulou M; Pegklidou K; Nicolaou I Bioorg Med Chem; 2013 Sep; 21(17):4951-7. PubMed ID: 23891165 [TBL] [Abstract][Full Text] [Related]
17. Residues affecting the catalysis and inhibition of rat lens aldose reductase. Carper DA; Hohman TC; Old SE Biochim Biophys Acta; 1995 Jan; 1246(1):67-73. PubMed ID: 7811733 [TBL] [Abstract][Full Text] [Related]
18. Identification of an aldose reductase inhibitor site by affinity labeling. Kador PF; Lee YS; Rodriguez L; Sato S; Bartoszko-Malik A; Abdel-Ghany YS; Miller DD Bioorg Med Chem; 1995 Oct; 3(10):1313-24. PubMed ID: 8564397 [TBL] [Abstract][Full Text] [Related]
19. Rhodanine-3-acetamide derivatives as aldose and aldehyde reductase inhibitors to treat diabetic complications: synthesis, biological evaluation, molecular docking and simulation studies. Bacha MM; Nadeem H; Zaib S; Sarwar S; Imran A; Rahman SU; Ali HS; Arif M; Iqbal J BMC Chem; 2021 Apr; 15(1):28. PubMed ID: 33906691 [TBL] [Abstract][Full Text] [Related]
20. Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex. Petrova T; Steuber H; Hazemann I; Cousido-Siah A; Mitschler A; Chung R; Oka M; Klebe G; El-Kabbani O; Joachimiak A; Podjarny A J Med Chem; 2005 Sep; 48(18):5659-65. PubMed ID: 16134934 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]